Literature DB >> 2556611

Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem.

F J van Spronsen1, R Berger, G P Smit, J B de Klerk, M Duran, C M Bijleveld, H van Faassen, M J Slooff, H S Heymans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2556611     DOI： 10.1007/BF03335416

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  7 in total

1.  Liver disorders in children: the indications for liver replacement in parenchymal and metabolic diseases.

Authors:  A P Mowat
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

2.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

3.  Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.

Authors:  R Berger; G P Smit; S A Stoker-de Vries; M Duran; D Ketting; S K Wadman
Journal:  Clin Chim Acta       Date:  1981-07-18       Impact factor: 3.786

4.  Orthotopic liver transplantation in children: two-year experience with 47 patients.

Authors:  J C Gartner; B J Zitelli; J J Malatack; B W Shaw; S Iwatsuki; T E Starzl
Journal:  Pediatrics       Date:  1984-07       Impact factor: 7.124

5.  Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.

Authors:  S K Wadman; M Duran; D Ketting; L Bruinvis; F J van Sprang; R Berger; G P Smit; B Steinmann; J V Leonard; P Divry; J P Farriaux; B Cartigny
Journal:  Clin Chim Acta       Date:  1983-05-30       Impact factor: 3.786

6.  Liver transplantation before 1 year of age.

Authors:  C O Esquivel; B Koneru; F Karrer; S Todo; S Iwatsuki; R D Gordon; L Makowka; W J Marsh; T E Starzl
Journal:  J Pediatr       Date:  1987-04       Impact factor: 4.406

7.  Pediatric liver transplantation: report on 52 patients with a 2-year survival of 86%.

Authors:  J B Otte; T Yandza; J de Ville de Goyet; K C Tan; M Salizzoni; B de Hemptinne
Journal:  J Pediatr Surg       Date:  1988-03       Impact factor: 2.545
  7 in total
  11 in total

1.  Tyrosinaemia type I with normal levels of plasma tyrosine.

Authors:  I T de Almeida; P P Leandro; M F Silva; C Silveira; A da Silva; J S de Sousa; M Duran
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.

Authors:  L J W M Pierik; F J van Spronsen; C M A Bijleveld; C M L van Dael
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Liver transplantation for hereditary tyrosinemia: the Quebec experience.

Authors:  K Paradis; A Weber; E G Seidman; J Larochelle; L Garel; C Lenaerts; C C Roy
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

4.  Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation.

Authors:  F J van Spronsen; G P Smit; F A Wijburg; Y Thomasse; G Visser; H S Heymans
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

5.  Liver transplantation in tyrosinaemia type I: the Groningen experience.

Authors:  F A Wijburg; W C Reitsma; M J Slooff; F J van Spronsen; H A Koetse; D J Reijngoud; G P Smit; R Berger; C M Bijleveld
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia.

Authors:  C J Wilson; K G Van Wyk; J V Leonard; P T Clayton
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

Review 7.  Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

Authors:  E Holme; S Lindstedt
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

8.  Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.

Authors:  H Schierbeek; G J Beukeveld; H van Faassen; F J van Spronsen; K Bijsterveld; E E Venekamp-Hoolsema; B G Wolthers; G P Smit
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

9.  Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis.

Authors:  S I Demers; D Phaneuf; R M Tanguay
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

10.  Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.

Authors:  M D Bain; P Purkiss; M Jones; P Bingham; T E Stacey; R A Chalmers
Journal:  Eur J Pediatr       Date:  1990-06       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.